SuperworthAmarin Corp Plc AMRN
- Market cap
- $249M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $186.2M
- −15% on a year ago
- Net margin
- −14.6%
- Free cash flow yield
- n/m
- not a meaningful number
Amarin Corp Plc trades at 1.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $186.2M over the last twelve months, down 15% on a year earlier with a −15% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $66.1M−27% | $74.7M−17% | $56.5M−34% | $67.5M−16% | $42.3M−36% | $62.3M−17% | $42M−26% | $72.7M+8% | $49.7M+17% | $49.2M−21% | $45.1M+7% | $42.2M−42% | |
| Cost of revenue | $36.2M+34% | $29.6M+11% | $24.6M−35% | $24.7M−34% | $26M−28% | $71.9M+143% | $16.9M−31% | $22.4M−10% | $27.5M+6% | $26.1M−64% | $27.4M+62% | $27.2M+22% |
| Gross profit | $29.8M−53% | $45.1M−29% | $31.9M−33% | $42.8M+0% | $16.3M−45% | −$9.6M | $25.1M−21% | $50.4M+18% | $22.2M+36% | $23.2M | $17.8M−29% | $15M−70% |
| R&D | $5.1M−11% | $5.8M+11% | $5.6M−2% | $4.7M−16% | $4.5M−11% | $6M+3% | $5.3M−5% | $4.9M+4% | $4.2M−7% | $5.4M−10% | $4.7M−12% | $4.8M−3% |
| SG&A | $45.5M−23% | $43.9M−36% | $39.9M−33% | $38.5M−24% | $36.9M−19% | $37M−16% | $36.6M−8% | $38.7M+0% | $19.7M−47% | $20.1M−46% | $21.1M−42% | $22.2M−43% |
| −$21.5M+317% | −$4.8M−50% | −$13.6M−22% | −$524K−98% | −$25.2M+17% | −$52.5M+986% | −$16.8M+23% | −$16M+2951% | −$11.1M−56% | −$6.3M−88% | −$11.3M−32% | −$12M−25% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$18.8M+384% | −$2.4M−64% | −$8.7M−40% | $2.9M | −$21.5M+15% | −$49.9M+1938% | −$13.6M+58% | −$13.4M | −$8.1M−62% | −$852K−98% | −$8.7M−36% | −$7.9M−42% |
| $501K−60% | $3.3M | $1.3M−34% | $1.4M | $3.6M+620% | −$1.3M | $2.1M+59% | $689K−50% | −$377K | $372K | $1.8M−13% | −$219K | |
| Net income | −$19.3M+276% | −$5.8M | −$10M−40% | $1.5M | −$25.1M+30% | −$48.6M+741% | −$15.7M+58% | −$14.1M | −$7.7M−69% | −$1.2M−98% | −$10.5M−33% | −$7.7M−46% |
| −$1.00+400% | −$0.20 | −$0.40−50% | $0.00 | −$1.20+20% | −$2.40+1100% | −$0.04−90% | −$0.03 | −$0.02−98% | $0.00 | −$0.03−25% | −$0.02−33% | |
| 20.4M+1% | 20.4M+1% | 20.5M+1% | 20.6M+1% | 20.6M+1% | 20.6M+1% | 413.4M+1916% | 414.5M+1915% | 415.5M+1921% | 416.1M+1923% | 419.1M+1% | 416.4M+1% |
Gross profit: 4 periods, Q1 FY13 to Q4 FY13: not printed by the filing, worked out from its own lines.
EPS, diluted: 10 periods, Q2 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent. Q4 FY11: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'.
Diluted shares: 9 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY19 to Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Amarin Corp Plc's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AMRNAmarin Corp Plc | $249M | n/m | 109× | 1.3× | −15% | −14.6% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| Peer median | $570.3M | 11.3× | 13.6× | 1.4× | +7% | 13.6% |
More on Amarin Corp Plc
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .